Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
Authors
Keywords
-
Journal
JOURNAL OF CUTANEOUS PATHOLOGY
Volume 44, Issue 2, Pages 158-176
Publisher
Wiley
Online
2016-11-10
DOI
10.1111/cup.12858
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Extensive tumoral melanosis associated with ipilimumab-treated melanoma
- (2016) K. Staser et al. BRITISH JOURNAL OF DERMATOLOGY
- Management of toxicities of immune checkpoint inhibitors
- (2016) Lavinia Spain et al. CANCER TREATMENT REVIEWS
- Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
- (2016) V.R. Belum et al. EUROPEAN JOURNAL OF CANCER
- BRAF inhibitor therapy–associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression
- (2016) Kumaran Mudaliar et al. HUMAN PATHOLOGY
- Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy
- (2016) Kurt B. Schaberg et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions
- (2016) George Jour et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma
- (2016) Mark C. Mochel et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Toxic Epidermal Necrolysis–like Reaction With Severe Satellite Cell Necrosis Associated With Nivolumab in a Patient With Ipilimumab Refractory Metastatic Melanoma
- (2016) Namrata Nayar et al. JOURNAL OF IMMUNOTHERAPY
- Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort
- (2016) Shelley Ji Eun Hwang et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma
- (2016) Shelley J.E. Hwang et al. MELANOMA RESEARCH
- Inverse Psoriasiform Eruption During Pembrolizumab Therapy for Metastatic Melanoma
- (2016) Mariam B. Totonchy et al. JAMA Dermatology
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
- (2016) Camille Hua et al. JAMA Dermatology
- Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1
- (2016) J. Naidoo et al. Cancer Immunology Research
- A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
- (2016) Marc Uemura et al. Journal for ImmunoTherapy of Cancer
- PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises
- (2015) F. Massari et al. CANCER TREATMENT REVIEWS
- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors
- (2015) C Ciccarese et al. Expert Opinion on Drug Metabolism & Toxicology
- Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis
- (2015) Omar Abdel-Rahman et al. Future Oncology
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
- (2015) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Acute skin reaction suggestive of pembrolizumab-induced radiosensitization
- (2015) Vincent Sibaud et al. MELANOMA RESEARCH
- A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab
- (2015) Giuliana Carlos et al. MELANOMA RESEARCH
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Drug-Associated Dermatomyositis Following Ipilimumab Therapy
- (2015) Shirwa Sheik Ali et al. JAMA Dermatology
- Histological Features Associated With Vemurafenib-Induced Skin Toxicities
- (2014) Jonathan L. Curry et al. AMERICAN JOURNAL OF DERMATOPATHOLOGY
- First report of ipilimumab-induced Grover disease
- (2014) J. Munoz et al. BRITISH JOURNAL OF DERMATOLOGY
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma
- (2014) Rachel L. Kyllo et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Ipilimumab-associated Sweet syndrome in a melanoma patient
- (2014) Rachel Gormley et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Ipilimumab in patients with cancer and the management of dermatologic adverse events
- (2014) Mario E. Lacouture et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
- (2014) R. W. Joseph et al. Cancer Immunology Research
- Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions
- (2013) Jonathan L. Curry et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysis
- (2013) Kira Minkis et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Sweet’s syndrome in a patient with metastatic melanoma after ipilimumab therapy
- (2013) Sofya Pintova et al. MELANOMA RESEARCH
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
- (2013) Caroline J. Voskens et al. PLoS One
- Ipilimumab induces simultaneous regression of melanocytic naevi and melanoma metastases
- (2012) F. Libon et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
- (2011) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Disseminated follicular eruption during therapy with the MEK inhibitor AZD6244
- (2011) Christiane Querfeld et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
- (2010) S. J. O'Day et al. ANNALS OF ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Development of the Anti–CTLA-4 Antibody Tremelimumab
- (2010) Antoni Ribas SEMINARS IN ONCOLOGY
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
- (2009) J. Weber et al. CLINICAL CANCER RESEARCH
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More